Regulatory work is rarely just about preparing a submission. By the time a team is approaching market access, the quality of the outcome is already shaped by earlier decisions: how the device was classified, how claims were defined, what evidence strategy was chosen, what documentation structure was built, and whether post-market obligations were considered early enough.
Regulatory Affairs at Qmed is built around that full picture. We help MedTech innovators define the right path, make the critical decisions at the right time, and turn those decisions into documentation and systems that can support approval and ongoing compliance. The aim is not to add layers. It is to reduce friction and maximize potential.
What sits inside this hub
This hub covers the consultancy side of the business: regulatory strategy, classification, quality management, technical documentation, UDI and EUDAMED support, post-market regulatory obligations, and selected market-access work.
Clinical Development sits inside this hub because it is where the evidence logic is shaped. It connects intended purpose, claims, risk, available data, evidence gaps, and study needs. In practice, that means it helps turn a broad regulatory objective into a clinical plan that can be justified, documented, and executed.
Where Clinical Development fits
Clinical Development is not a parallel department competing with Clinical Affairs. It is the bridge between strategy and execution.
This is the part of the work where teams clarify what the device needs to prove, what can be supported with existing data, what still has to be generated, and how that evidence story should be documented. Typical outputs can include clinical development planning, clinical evaluation inputs, PMCF planning, literature strategy, protocol input, and other evidence-linked documentation that sits behind regulatory progress.
Support across the lifecycle
Plan
We help define the route before the downstream work becomes expensive. That can include regulatory strategy, classification, evidence planning, market sequencing, quality-system foundations, and early decisions that shape the entire programme.
Market Access
As the project matures, we support the work that proves readiness: technical documentation, CER support, submission planning, UDI and EUDAMED readiness, and the broader documentation structure that needs to hold together under review.
Post-Market
Once the product is on the market, regulatory pressure does not reduce. It changes form. We support PMS-related work, PSUR preparation, documentation updates, PMCF interfaces, quality-system maintenance, and the broader operating model needed to stay compliant over time.
Why teams use Qmed
Teams usually come to us when they can see that the next regulatory step depends on more than one missing item. It may look like a documentation issue, but the real problem is often earlier: unclear classification, an incomplete evidence strategy, a weak link between claims and available data, or post-market obligations that were not planned into the system early enough.
That’s where Qmed should feel different. We’re European-focused in a real sense—not just in messaging. We understand the regional landscape, how regulatory and clinical work interact, and the level of detail needed to move a project forward without losing sight of the commercial goal.
Typical situations
Usually, medtech innovators are experiencing one or more of the following:
- key regulatory decisions are still open, but execution is already starting
- the documentation is growing without one clear structure behind it
- the clinical evidence story is weaker than the intended claims require
- the team needs experienced support without building a large internal regulatory function
- post-market obligations are approaching, but the system behind them is still immature
Talk to Qmed
Tell us about your next milestone, the device you’re developing, which markets you’re targeting, and any regulatory questions or evidence gaps you’re facing.